GH Research PLC (GHRS) Stock AnalysisGHRSGH Research PLC

GH Research PLC is a clinical-stage biopharmaceutical company. The Company is focusing on developing its novel and proprietary mebufotenin therapies for the treatment of patients with treatment-resistant depression (TRD). Its portfolio includes GH001, its proprietary inhalable mebufotenin product candidate and GH002, its proprietary intravenous mebufotenin product candidate. GH001 is delivered via a vaporization device produced by a third party, and the Company is developing a proprietary aerosol delivery device which is in clinical investigation in Europe. GH001 completed two Phase 1 clinical trials in healthy volunteers, a Phase 1/2 trial in TRD and two Phase 2a proof-of-concept trials. GH002 Completed a randomized, double-blind, placebo-controlled, dose-ranging clinical pharmacology trial of GH002 in healthy volunteers, and it is developing GH002 within its focus area of psychiatric and neurological disorders. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

GH Research PLC is a good buy right now due to its current price of $18.07, which is significantly lower than the average analyst price target of $40, indicating a potential upside of over 121%. Additionally, despite recent losses, the stock has shown a year-to-date change of +36.48%, reflecting strong market interest. The main risk is its low RSI of 27.176, indicating it may be oversold, which could lead to further price declines in the short term.